According to the Zhidao Financial APP, Cansinobio (06185) rose nearly 4%, as of press time, up 3.74%, at HKD 20.75, with a turnover of HKD 7.7283 million.

Recently, Cansinobio announced that its board of directors, Xuefeng Yu, Ph.D. (Chairman of the Board, CEO, General Manager, and one of the controlling shareholders), Dr. ShouBai CHAO (Executive Director, COO, and Deputy General Manager), Dr. Zhu Tao (Chief Scientific Officer, Deputy General Manager, and one of the controlling shareholders), and Ms. Wang Jing (Executive Director, Chief Business Officer, and Deputy General Manager), informed that they intend to purchase the company's H-shares from the public market within six months from the date of this announcement, subject to applicable laws and regulations.

According to the announcement, the so-called prospective shareholders intend to increase their holdings, and the total cost of the expected increase in shareholding will not exceed HKD 10 million. In addition, the group of potential shareholders has stated that the purchased H shares will be used for medium-to-long-term investments, and they have no intention to sell the H shares within six months after the increase. The funds required to increase their holdings will come from the company's own funds or other financing.